Caris Life Sciences

CAI

Market cap $5.38B

Caris AI Insights are proprietary and only available to Caris Life Sciences customers   IRVING, Texas, March 16, 2026 /PRNewswire/ -- Caris Life Sciences ® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced the addition of a platinum resistance AI signature to the growing portfolio of Caris AI Insights™. This new signature is designed to predict early platinum resistance in patients with high-grade serous ovarian cancer (HGSOC) and provides clinicians with unprecedented molecular insight into how long a patient may benefit from first-line platinum-based chemotherapy.

IRVING, Texas, March 11, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced that the company and collaborators from leading cancer centers, will collectively present five studies at the 2026 United States and Canadian Academy of Pathology (USCAP) Annual Meeting in San Antonio, Texas to be held March 21-26, 2026. Caris' robust multimodal database, comprised of Whole Exome Sequencing (WES), Whole Transcriptome Sequencing (WTS), IHC and real-world clinical data, was used to generate the results being presented.

Caris AI Insights are proprietary and only available to Caris Life Sciences customers IRVING, Texas, March 9, 2026 /PRNewswire/ -- Caris Life Sciences ® (NASDAQ: CAI), a leading patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced the launch of a novel, proprietary Caris AI Insights™ signature for pancreatic cancer included in the Caris Molecular Tumor Board Report.  The Caris Molecular Tumor Board Report is an innovative tumor profiling report that provides an additional tumor biology resource and is available upon request with no additional tissue sampling required when ordering MI Cancer Seek®.

Investors with an interest in Medical Services stocks have likely encountered both BrightSpring Health Services, Inc. (BTSG) and Caris Life Sciences,?Inc. (CAI). But which of these two stocks presents investors with the better value opportunity right now?

Caris Life Sciences, Inc. (CAI) Q4 2025 Earnings Call Transcript

Caris Life Sciences Inc. (NASDAQ: CAI) on Thursday posted better-than-expected fourth-quarter earnings.

Caris Life Sciences Inc. (NASDAQ: CAI) shares are up during Friday's premarket session following better-than-expected fourth-quarter earnings and a significant interim readout from the company's Achieve 1 study.

Demonstrates Superior Sensitivity and Specificity of Caris Detect Results demonstrate the superiority of Whole Genome Sequencing compared to methylation-based approaches IRVING, Texas, Feb. 26, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced an interim readout of Achieve 1, the Company's study supporting the upcoming launch of Caris Detect™, its multi-cancer early detection (MCED) test. This interim readout of Achieve 1 represents a major milestone in Caris' goal to detect cancer earlier, when it is most treatable, through Whole Genome Sequencing, advanced AI and molecular insights.

Full year revenue growth of 97% driven by strong performance in molecular profiling services Expects full year 2026 revenue to be in the range of $1.0 billion to $1.02 billion IRVING, Texas, Feb. 26, 2026 /PRNewswire/ -- Caris Life Sciences®, Inc. (NASDAQ: CAI), a leading, patient centric, next-generation AI TechBio company and precision medicine pioneer, today reported financial results for the quarter and full year ended December 31, 2025. Fourth Quarter 2025 Financial Highlights Reported total revenue of $292.9 million, an increase of 125% over the corresponding prior year period.

IRVING, Texas, Feb. 24, 2026 /PRNewswire/ -- Caris Life Sciences ® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced a new breast cancer signature included in the Caris Molecular Tumor Board Report. The Caris Molecular Tumor Board Report is an innovative research-use-only (RUO) tumor profiling report that provides an additional tumor biology resource and is available upon request when ordering MI Cancer Seek®.